🇺🇸 FDA
Pipeline program

Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion

PROICM 2021-04 REL

Phase 2 small_molecule active

Quick answer

Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion for Neuroendocrine tumor is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Neuroendocrine tumor
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials